Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00160576
Status:
COMPLETED
Last Update Posted:
2013-12-06
First Post:
2005-09-08
Brief Title:
Levetiracetam Treatment in Adult Subjects With Parkinsons Disease Experiencing Troublesome Dyskinesias
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Therapeutic Exploratory Single Arm Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mgDay 500mg Oral Tablets on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 41-week trial composed of two consecutive parts Part A 14 weeks and optional Part B 27 weeks to evaluate the efficacy of levetiracetam in controlling levodopa induced dyskinesias in adults with Idiopathic Parkinsons Disease without negative impact on the benefit on the motor function of the antiparkinsonian treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None